Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma

Geraldine Faivre, Matthew James Butler, Isabelle Le, Andrew Brenner

Resultado de la investigación: Articlerevisión exhaustiva

6 Citas (Scopus)

Resumen

Optimal management of elderly patients with primary central nervous system lymphoma (PCNSL) after induction therapy is unclear. In our retrospective series of 10 patients treated with temozolomide after induction with R-MPV (rituximab, methotrexate, procarbazine and vincristine) we found a median progression-free survival of 57 months, and a median overall survival of 63 months, with moderate toxicity, which supports the idea that temozolomide might have activity for maintenance in elderly patients with PCNSL.

Idioma originalEnglish (US)
Páginas (desde-hasta)665-669
Número de páginas5
PublicaciónClinical Lymphoma, Myeloma and Leukemia
Volumen19
N.º10
DOI
EstadoPublished - oct. 2019

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Huella

Profundice en los temas de investigación de 'Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma'. En conjunto forman una huella única.

Citar esto